Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alfredo Berruti

Showing results (11-20 of 379) with videos related to

Pageof 38
Sort By:
The New England Journal of Medicine|October 2, 2014
Exemestane with ovarian suppression in premenopausal breast cancerVito Amoroso, Alfredo Berruti, Edda Simoncini
The New England Journal of Medicine|December 21, 2012
Enzalutamide in prostate cancer after chemotherapyAlfredo Berruti, Daniele Generali, Marco Tampellini
The New England Journal of Medicine|June 2, 2009
Endocrine therapy plus zoledronic acid in premenopausal breast cancerAlfredo Berruti, Consuelo Buttigliero, Luigi Dogliotti
Annals of Translational Medicine|October 29, 2019
Neoadjuvant androgen deprivation therapy through intense inhibition of the androgen target: "<i>Midsummer Night's Dream</i>" or "<i>Much Ado About Nothing</i>"?Alessandro Antonelli, Carlotta Palumbo, Alfredo Berruti
The New England Journal of Medicine|May 13, 2011
Advances in pancreatic neuroendocrine tumor treatmentAlfredo Berruti, Anna Pia, Massimo Terzolo
The New England Journal of Medicine|August 26, 2011
Abiraterone and increased survival in metastatic prostate cancerAlfredo Berruti, Anna Pia, Massimo Terzolo
European Urology|October 24, 2008
Re: Christan Walter, Bilal Al-Nawas, Knut A. Grötz, et al. Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate. Eur Urol 2008;54:1066-72Alfredo Berruti, Cinzia Ortega, Vittorio Fusco
Endocrine|January 14, 2021
Maintenance everolimus beyond progression in pancreatic NET to control insulinoma syndromeValeria Tovazzi, Vittorio D Ferrari, Alfredo Berruti
The New England Journal of Medicine|December 22, 2021
Lutetium-177-PSMA-617 for Prostate CancerAlberto Dalla Volta, Salvatore Grisanti, Alfredo Berruti
Journal of the National Cancer Institute. Monographs|November 2, 2011
The treatment of individual patients is more than a trialAlberto Bottini, Alfredo Berruti, Daniele Generali, et al.
Pageof 38

Showing results (11-20 of 379) with videos related to

Sort By:
Pageof 38
The New England Journal of Medicine|October 2, 2014
Exemestane with ovarian suppression in premenopausal breast cancerVito Amoroso, Alfredo Berruti, Edda Simoncini
The New England Journal of Medicine|December 21, 2012
Enzalutamide in prostate cancer after chemotherapyAlfredo Berruti, Daniele Generali, Marco Tampellini
The New England Journal of Medicine|June 2, 2009
Endocrine therapy plus zoledronic acid in premenopausal breast cancerAlfredo Berruti, Consuelo Buttigliero, Luigi Dogliotti
Annals of Translational Medicine|October 29, 2019
Neoadjuvant androgen deprivation therapy through intense inhibition of the androgen target: "<i>Midsummer Night's Dream</i>" or "<i>Much Ado About Nothing</i>"?Alessandro Antonelli, Carlotta Palumbo, Alfredo Berruti
The New England Journal of Medicine|May 13, 2011
Advances in pancreatic neuroendocrine tumor treatmentAlfredo Berruti, Anna Pia, Massimo Terzolo
The New England Journal of Medicine|August 26, 2011
Abiraterone and increased survival in metastatic prostate cancerAlfredo Berruti, Anna Pia, Massimo Terzolo
European Urology|October 24, 2008
Re: Christan Walter, Bilal Al-Nawas, Knut A. Grötz, et al. Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate. Eur Urol 2008;54:1066-72Alfredo Berruti, Cinzia Ortega, Vittorio Fusco
Endocrine|January 14, 2021
Maintenance everolimus beyond progression in pancreatic NET to control insulinoma syndromeValeria Tovazzi, Vittorio D Ferrari, Alfredo Berruti
The New England Journal of Medicine|December 22, 2021
Lutetium-177-PSMA-617 for Prostate CancerAlberto Dalla Volta, Salvatore Grisanti, Alfredo Berruti
Journal of the National Cancer Institute. Monographs|November 2, 2011
The treatment of individual patients is more than a trialAlberto Bottini, Alfredo Berruti, Daniele Generali, et al.
Pageof 38